City of Hope scientists have developed and tested the first chimeric antigen receptor therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published March 4 in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.
Glioblastoma patients with immunologic response to the VBI-1901 vaccine had a higher overall survival rate than non-vaccine responders.
Many patients with rare, fast-growing neuroendocrine tumors respond well to a combination of ipilimumab and nivolumab, according to the first peer-reviewed publication out of DART, a rare cancer clinical trial.
The best approach for surgeons to identify malnourished cancer patients before they have a cancer operation may be related to the cancer type, according to an article published in the Journal of the American College of Surgeons.
The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.
Although one in seven adults smoke cigarettes the year prior to undergoing weight-loss surgery, nearly all successfully quit at least a month before their operation. However, smoking prevalence steadily climbs to pre-surgery levels within seven years, according to new research led by the University of Pittsburgh Graduate School of Public Health.
Patients who underwent a stem cell transplant and received the Triplex vaccine to prevent a type of herpes virus, cytomegalovirus, from duplicating out of control were 50% less likely to develop health complications related to the virus than patients who did not take Triplex, according to a City of Hope-led study published today in Annals of Internal Medicine.
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.
The phase III KEYNOTE-355 trial investigating Keytruda in combination with chemotherapy met one of its dual primary endpoints of progression-free survival in patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10).
The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.
